Standing behind the counter and waiting for customers to walk into your pharmacy is not enough to sustain independents in today’s marketplace. Here are some new or unique things independents should consider to ensure survival, says B. Douglas Hoey, RPh, MBA, CEO of the NCPA.
FDA Issues CRL for Heplisav-B in Adults With ESRD on Hemodialyis
May 14th 2024Dynavax plans to meet with the FDA to discuss how the company can provide additional data to support the approval of its 4-dose Heplisav-B regimen and expand protection for adults with end-stage renal disease (ESRD) on hemodialysis.